Please login to the form below

trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

Roche preps new Kadcyla filings after phase 3 trial win

In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,

Latest news

Ocrevus surge keeps Roche smiling in Q3

Meanwhile, breast cancer therapy Herceptin (trastuzumab) also continued its European decline thanks to biosimilar competition, failing 10%, but grew 2% to CHF 5.3bn overall and is once again Roche’s
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or
AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

The Institute had already rejected it in this setting in June, but looked again to see if the arrival of biosimilars of Herceptin (trastuzumab) – which is administered with Perjeta – would help ... NICE already recommends Perjeta with trastuzumab and
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

Pfizer has gained European approval for its Herceptin (trastuzumab) biosimilar product, Trazimera.

More from news
Approximately 14 fully matching, plus 140 partially matching documents found.

Latest Intelligence

2016: The year when deal-makers took stock?

Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .
Deal Watch October 2016

Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.
An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S
Tough times for pharma in Portugal

In other cases there is a significant decrease in spending on drugs such as Roche's Herceptin (trastuzumab) for breast cancer, which the company explains through price reductions.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

AVEO's financial head joins ImmunoGen

cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Director development role to Business Director, H...: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Manager / Account Director: Competative

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Associate Director: £75, 000-90, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Medical Writer: Salary TBC

Global Business Development Director – Health Education: excellent commission

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Healthcare Marketing – Berks: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...